Valuation: TAUNS Laboratories,Inc.

Market Cap 51.91B 321M 282M 260M 243M 456M 30.3B 464M 3.12B 1.21B 14.94B 1.21B 1.18B P/E 2025
8.67x
P/E 2026 * 9.79x
Enterprise Value 58.74B 363M 319M 294M 275M 516M 34.29B 525M 3.53B 1.37B 16.9B 1.36B 1.33B EV / Sales 2025
3.23x
EV / Sales 2026 * 4.06x
Free-Float
29.82%
Yield 2025
5.2%
Yield 2026 * 7.24%
1 day-0.41%
1 week-0.41%
Current month-2.22%
1 month-2.22%
3 months-7.44%
6 months-5.83%
Current year-4.72%
1 week 485
Extreme 485
490
1 month 484
Extreme 484
498
Current year 484
Extreme 484
568
1 year 484
Extreme 484
603
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 01/05/2014
Director of Finance/CFO 66 01/11/2018
Corporate Officer/Principal 38 01/07/2022
Director TitleAgeSince
Director/Board Member 62 01/09/2020
Director/Board Member 52 01/04/2016
Director/Board Member 38 01/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.41%-0.41%-13.39% - 321M
+4.37%+8.47%+186.45%+302.31% 18.95B
+0.50%+2.10%-41.14%-21.98% 9.41B
+3.97%+4.96%+35.33%+17.82% 7.1B
+3.03%+1.25%-29.25% - 5.29B
+2.11%+1.38%-25.78%-31.24% 4.92B
+3.27%+2.81%+206.43%-34.58% 4.54B
+5.55%-2.29%+97.99%+101.60% 4.42B
+1.17%+3.26%-28.53%-29.48% 4.01B
-0.87%-2.92%-21.23%-44.47% 2.49B
Average +2.27%+2.08%+36.69%+32.50% 6.14B
Weighted average by Cap. +2.99%+4.17%+70.21%+99.56%

Financials

2025 2026 *
Net sales 19.06B 118M 104M 95.43M 89.23M 167M 11.13B 170M 1.14B 443M 5.48B 443M 433M 14.76B 91.29M 80.19M 73.88M 69.08M 130M 8.61B 132M 886M 343M 4.25B 343M 335M
Net income 6.5B 40.21M 35.32M 32.54M 30.43M 57.07M 3.79B 58.11M 390M 151M 1.87B 151M 148M 5.2B 32.18M 28.26M 26.04M 24.35M 45.67M 3.04B 46.51M 312M 121M 1.5B 121M 118M
Net Debt 6.83B 42.25M 37.11M 34.19M 31.97M 59.96M 3.99B 61.06M 410M 159M 1.97B 159M 155M 7.99B 49.45M 43.44M 40.02M 37.42M 70.19M 4.67B 71.48M 480M 186M 2.3B 186M 182M
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
26/06/26 JPY 485.00 -0.41% 349,900
25/06/26 JPY 487.00 0.00% 141,300
24/06/26 JPY 487.00 +0.21% 89,000
23/06/26 JPY 486.00 -0.61% 117,400
22/06/26 JPY 489.00 +0.41% 174,300
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
487.00JPY
Average target price
420.00JPY
Spread / Average Target
-13.76%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 197A Stock